Cubist Systematic Strategies, LLC Mei Pharma, Inc. Transaction History

Cubist Systematic Strategies, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.42 - $0.65 $4,925 - $7,623	11,728 New	11,728 $7,000
Q3 2021 Nov 15, 2021	SELL	$2.52 - $2.99 $3,631 - $4,308	-1,441 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$2.6 - $3.65 $3,746 - $5,259	1,441 New	1,441 $4,000
Q4 2020 Feb 16, 2021	SELL	$2.6 - $3.32 $4,474 - $5,713	-1,721 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$2.46 - $4.27 $19,655 - $34,117	-7,990 Reduced 82.28%	1,721 $5,000

Q2 2020 Aug 14, 2020	BUY	$1.45 - $4.3 $14,080 - $41,757	9,711 New	9,711 $40,000
Q1 2020 May 15, 2020	SELL	$0.75 - $2.55 $10,752 - $36,556	-14,336 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.65 - $2.48 $23,654 - $35,553	14,336 New	14,336 $36,000
Q3 2019 Nov 14, 2019	SELL	$1.48 - $2.52 $27,027 - $46,020	-18,262 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$2.45 - $3.32 $44,741 - $60,629	18,262 New	18,262 $46,000
Q4 2018 Feb 14, 2019	SELL	$1.92 - $4.1 $23,967 - $51,180	-12,483 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$3.39 - $4.61 $5,796 - $7,883	1,710 Added 15.87%	12,483 $54,000
Q2 2018 Aug 14, 2018	BUY	$1.89 - $4.95 $20,360 - $53,326	10,773 New	10,773 $42,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $373M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.